Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected |
| |
Authors: | Gutiérrez Carolina Díaz Laura Vallejo Alejandro Hernández-Novoa Beatriz Abad María Madrid Nadia Dahl Viktor Rubio Rafael Moreno Ana M Dronda Fernando Casado José Luis Navas Enrique Pérez-Elías María Jesús Zamora Javier Palmer Sarah Muñoz Eduardo Muñoz-Fernández María Ángeles Moreno Santiago |
| |
Affiliation: | Infectious Diseases Department, Hospital Universitario Ramón y Cajal, and IRYCIS, Madrid, Spain. |
| |
Abstract: | ObjectiveThe primary objective was to assess the effect of MVC intensification on latently infected CD4+ T cells in chronically HIV-1-infected patients receiving antiretroviral therapy.MethodsWe performed an open-label pilot phase II clinical trial involving chronically HIV-1-infected patients receiving stable antiretroviral therapy whose regimen was intensified with 48 weeks of maraviroc therapy. We analyzed the latent reservoir, the residual viremia and episomal 2LTR DNA to examine the relationship between these measures and the HIV-1 latent reservoir, immune activation, lymphocyte subsets (including effector and central memory T cells), and markers associated with bacterial translocation.ResultsOverall a non significant reduction in the size of the latent reservoir was found (p = 0.068). A mean reduction of 1.82 IUPM was observed in 4 patients with detectable latent reservoir at baseline after 48 weeks of intensification. No effect on plasma residual viremia was observed. Unexpectedly, all the patients had detectable 2LTR DNA circles at week 24, while none of them showed those circles at the end of the study. No changes were detected in CD4+ or CD8+ counts, although a significant decrease was found in the proportion of HLA-DR+/CD38+ CD4+ and CD8+ T-cells. LPS and sCD14 levels increased.ConclusionsIntensification with MVC was associated with a trend to a decrease in the size of the latent HIV-1 reservoir in memory T cells. No impact on residual viremia was detected. Additional studies with larger samples are needed to confirm the results.Trial RegistrationClinicalTrials.gov {"type":"clinical-trial","attrs":{"text":"NCT00795444","term_id":"NCT00795444"}}NCT00795444 |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|